Viva Biotech Limited

Viva Biotech Limited, established in 2008, is a Chinese company specializing in drug discovery services and investments. The company offers a comprehensive range of services, including early-stage structure-based drug research and development (R&D) and commercial manufacturing, catering to global biopharmaceutical innovators. Their expertise spans various therapeutic strategies and drug modalities, encompassing both small molecules and biologics across the pharmaceutical and biotechnology sectors. The experienced chemistry team, led by senior medicinal chemists and drug discovery biologists, provides services for drug design, medicinal chemistry (hit to lead and lead optimization), custom synthesis, chemical analysis and purification, kilogram scale-up, peptide synthesis, and corresponding bioassays. Additionally, Viva Biotech operates a subsidiary, Langhua Pharma, which offers integrated Chemical, Manufacturing, and Control (CMC) services from preclinical to commercial manufacturing. The company also employs an equity-for-service (EFS) model to support high-potential startups addressing unmet medical needs. Viva Biotech's investment division, Viva BioInnovator, is dedicated to identifying and supporting early-stage biotech startups globally. With over $150 million invested across 91 portfolio companies, Viva BioInnovator aims to catalyze innovation and growth in the biotech sector. The division focuses on providing funding, guidance, and support to founders with innovative ideas, assisting in the development of transformative therapeutics. Their portfolio includes companies involved in various areas such as cancer detection and treatment, opioid overdose intervention, and carbon capture technology. The company's global presence includes facilities in Shanghai, San Diego, Boston, Jiaxing, Chengdu, Hangzhou, Taizhou, Ningbo, Suzhou, Hong Kong, and Belgium. In December 2024, Viva Biotech officially established a branch in Boston, USA, marking a significant milestone in its global expansion strategy. This move aims to enhance international collaboration networks and provide comprehensive one-stop CRO-CMC/CDMO services—from drug discovery and preclinical development to commercial manufacturing—for clients worldwide. The Boston branch serves as a crucial hub within Viva Biotech's global network, connecting operations in China, the United States, the United Kingdom, Europe, and other regions, forming an efficient global operational system poised to respond swiftly and precisely to the evolving landscape of drug discovery and development, as well as the increasingly diverse needs of clients. As of June 30, 2025, Viva Biotech had provided drug R&D and manufacturing services to 2,574 biotech and pharmaceutical clients worldwide and invested in and incubated 93 biotech startups. The company continues to strengthen its technological capabilities and improve R&D and production levels to provide high-quality and diversified services for more drug discovery startups, as well as medium and large pharmaceutical enterprises around the world.